The nation’s largest pharmacy benefits manager (PBM) Casey Bozeman Company Overview Integrated PBM services, including: network-pharmacy claims processing drug-utilization review formulary management mail-order pharmacy service benefit-design consultation medical & drug data analysis services Clients include government agencies, corporations, and labor unions Company Overview, cont’d 1.4 billion prescriptions managed annually 135 million patients (1 in 3 Americans) $94 billion in revenue in past 12 months Doubled in size with acquisition of Medco in April 2012 Traded on NASDAQ as ESRX Company Overview, cont’d Headquartered in Cool Valley, Missouri George Paz, President & CEO since 2005 CPA, Financial genius, PR nightmare #6 most highly-compensated CEO in U.S.: $52M (Forbes) Not a single pharmacist on his leadership team Earlier News Stories (prior to 2013) Bitter contract dispute with Walgreens, nation’s largest drugstore chain No contract for 9 months in 2011 Walgreens suffered nearly 30% loss in script volume, ESRX barely flinched New contract agreed upon in September 2012 Background info sources: Express-Scripts.com, Wikipedia, Insider-Monkey.com January 22, 2013 Five Pharmacies Now Dominate U.S. Prescription Dispensing CVS Caremark, Walgreens, Express Scripts, Rite Aid, and Walmart 63% of U.S. Rx dispensing revenues in 2012 Healthcare reform will benefit these companies, due to increase in total Rx spending BusinessWire.com January 23, 2013 Express Scripts Lays Off 330 Employees Nationwide Layoffs across 55 different sites 100 employees in a former Medco office in NJ were impacted Memphis Business Journal February 7, 2013 Express Scripts Bleeds the Medco Ranks, Again “Express Scripts is reportedly telling up to 200 workers to accept a pay cut of up to 40 percent or leave...” Medco acquisition cost $29 billion last spring Suspicion that ESRX may abandon Medco’s HQ in New Jersey Pharmalive.com Q1 2013 Express Scripts Labs: ScreenRx Express Scripts’ proprietary solution Uses 400 known factors about the patient, MD, the disease, and the medication to predict non-compliance before it happens Up to 98% accuracy Pharmacist can intervene to help high-risk patients Lab.Express-Scripts.com February 19, 2013 Express Scripts Accuses Ernst & Young of Stealing Trade Secrets One of E&Y’s former partners allegedly snuck into ESRX facilities several times in 2012, emailed confidential files to himself Over 200,000+ pages of pricing info, business projections and strategy were stolen “Evil motive”: to boost E&Y’s own healthcare business Complaint seeks damages plus a court order barring the disclosure of the stolen data Reuters.com February 19, 2013 Express Scripts 4Q Profit Jumps 74% More pts used generic drugs, increasing ESRX’s profitability Patents expired on many common drugs ESRX continued to absorb Medco Successful contract with Walgreens contributed greatly ESRX has very low operating margins: ~5% PharmPro.com (Associated Press) Q2 2013 Express Scripts Labs: Rx Abuse & Pharmacy Fraud More Deadly than Cocaine & Heroin Combined 15,000+ Americans die annually from prescription drug OD Estimated 3-10% of healthcare spending is lost to fraud in U.S. Express Scripts data analytics uncovers patterns of potential fraud/abuse Estimated savings due to 435 cases referred to authorities by ESRX in 2011: $500M Lab.Express-Scripts.com March 15, 2013 Express Scripts: Best Places to Work Finalist St. Louis Business Journal Employees must adopt a “can-do” attitude Culture is one of “high energy” St. Louis Business Journal April 1, 2013 3 Reasons to Buy Express Scripts Motley Fool says ESRX stock is a “Buy”: $290 billion in drugs coming off patent over the next 5 years Aging population ObamaCare: many more people will have Rx insurance Motley Fool (Fool.com) April 8, 2013 Bonuses are Back at Express Scripts ESRX share price rose 21% in 2012 vs. S&P 500 increase of 13.4% Revenue more than doubled March 28, 2013 Express Scripts CEO’s Compensation Jumps 50% St. Louis Today (STLToday.com), Yahoo! News (news.yahoo.com) Stock Trend, YTD Stock Trend, YTD vs. NASDAQ Stock Trend, 10 yr To Buy or Not to Buy? If it’s good enough for the Fool… EPS has consistently risen since 2006 Long-term earnings potential, staying power, and negotiating power To Work or Not to Work? I’d rather not…